Oral small molecule GLP-1 receptor agonist
Lotiglipron 260 mg tablet once daily
LOTI_PO_260MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.32 (-10.61 to 1.08) | 0.82 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.79 (0.43 to 6.99) | 0.29 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.69 (3.64 to 16.78) | 0.10 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.53 (3.51 to 12.26) | 0.17 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 11.57 (5.23 to 26.91) | 0.11 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.65 (1.39 to 5.12) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.78 (2.19 to 10.69) | 0.13 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.89 (0.05 to 13.47) | 0.47 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.46 (0.01 to 15.95) | 0.57 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -5.22 (-11.08 to 1.83) | 0.44 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.84 (0.38 to 8.48) | 0.37 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 6.83 (2.72 to 17.00) | 0.17 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.87 (2.53 to 9.45) | 0.34 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 9.91 (3.65 to 29.22) | 0.21 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.97 (0.91 to 4.36) | 0.49 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.44 (1.30 to 9.30) | 0.29 |